Literature DB >> 2863917

Edrophonium and neostigmine for reversal of the neuromuscular blocking effect of vecuronium.

J Engbaek, H Ording, D Ostergaard, J Viby-Mogensen.   

Abstract

The effect of edrophonium for reversal of the non-depolarizing neuromuscular blockade produced by a continuous infusion of vecuronium was compared to that of neostigmine in 20 adult patients during neurolept anaesthesia. When antagonism was attempted at 10% twitch height recovery, reversal time to a train-of-four ratio of 0.7 was significantly shorter following neostigmine 0.04 mg/kg than after edrophonium 0.75 mg/kg (9.8 min and 18.7 min, respectively) but the same after edrophonium 1.5 mg/kg (10.3 min). There was no statistically significant difference in reversal time between neostigmine 0.04 mg/kg given at 10% twitch height and edrophonium 0.75 mg/kg given at 25% twitch height recovery (6.0 min). Additional doses of atropine were necessary following edrophonium 1.5 mg/kg.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2863917     DOI: 10.1111/j.1399-6576.1985.tb02250.x

Source DB:  PubMed          Journal:  Acta Anaesthesiol Scand        ISSN: 0001-5172            Impact factor:   2.105


  4 in total

1.  The current status of edrophonium: have we come "full circle"?

Authors:  A F Kopman
Journal:  Can J Anaesth       Date:  1991-03       Impact factor: 5.063

2.  Priming with anti-cholinesterases--the effect of different combinations of anti-cholinesterases and different priming intervals.

Authors:  M Naguib; M Abdulatif
Journal:  Can J Anaesth       Date:  1988-01       Impact factor: 5.063

3.  Priming with anti-cholinesterases--the effect of different priming doses of edrophonium.

Authors:  M Naguib; M Abdulatif
Journal:  Can J Anaesth       Date:  1988-01       Impact factor: 5.063

4.  Neostigmine and edrophonium for reversal of pipecuronium neuromuscular blockade.

Authors:  M Abdulatif; M Naguib
Journal:  Can J Anaesth       Date:  1991-03       Impact factor: 5.063

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.